Remus Pharma.

What does Remus Pharma. do?

Remus Pharmaceuticals Ltd is a Small Cap company in the Pharmaceuticals & Biotechnology industry, recently transitioned to public status in January 2023. Key metrics include a market cap of Rs 1,170 Cr, a P/E ratio of 40.00, and a return on equity of 33.47%.

Overview: <BR>Remus Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Small Cap company.<BR><BR>History: <BR>Remus Pharmaceuticals Ltd was originally incorporated as Remus Pharmaceuticals Private Limited in 2015. The company transitioned from a Private to Public entity and changed its name to Remus Pharmaceuticals Limited on January 06, 2023. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: Rs 1,170 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 40.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.05% <BR>Debt-Equity: -0.20 <BR>Return on Equity: 33.47% <BR>Price-to-Book: 13.50 <BR><BR>Contact Details: <BR>Address: Not available <BR>Phone: Not available <BR>Email: Not available <BR>Website: Not available

When is the next results date for Remus Pharma.?

No Upcoming Board Meetings

Has Remus Pharma. declared dividend?

Remus Pharmaceuticals Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of November 19, 2024. Recent total returns show significant volatility, with a -22.04% return over the last 6 months, but a strong 253.49% return over the past 2 years.

Remus Pharmaceuticals Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 19 Nov 24<BR><BR>Dividend Yield: 0.05%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -22.04%, the dividend return was 0%, resulting in a total return of -22.04%.<BR><BR>Over the past year, the price return was -6.6%, the dividend return was 0.05%, leading to a total return of -6.55%.<BR><BR>In the last 2 years, the price return was 252.22%, the dividend return was 1.27%, which resulted in a total return of 253.49%.<BR><BR>For the 3-year period, the price return was 0%, the dividend return was 0%, resulting in a total return of 0.0%.<BR><BR>In the last 4 years, the price return was 0%, the dividend return was 0%, leading to a total return of 0.0%.<BR><BR>Over the past 5 years, the price return was 0%, the dividend return was 0%, resulting in a total return of 0.0%.<BR><BR>Overall, Remus Pharmaceuticals Ltd has declared a dividend, but the recent total returns indicate significant volatility, particularly in the shorter periods, with a notable decline in the last 6 months and 1 year. However, the 2-year total return shows a strong performance, suggesting potential recovery or growth in the longer term.

What is the bonus history of Remus Pharma.?

Remus Pharma's recent bonus history includes a 1:1 bonus announced on July 4, 2025, and a 3:1 bonus issued on June 6, 2024, rewarding shareholders with additional shares based on their existing holdings.

Remus Pharma has a notable bonus history. The most recent bonus issue was a 1:1 bonus announced with an ex-date of July 4, 2025. Prior to that, on June 6, 2024, the company issued a 3:1 bonus. This indicates that shareholders are rewarded with additional shares based on their existing holdings during these bonus issues. If you have any more questions about Remus Pharma or need further details, feel free to ask!

Who are the peers of the Remus Pharma.?

Remus Pharma's peers include Hester Bios, Themis Medicare, Lincoln Pharma, Wanbury, Kopran, Kilitch Drugs, Bharat Parenter, Shukra Pharma, and Fermenta Biotec. Key insights show excellent growth and capital structure for Remus Pharma, with Wanbury having the highest 1-year return at 39.83% and Hester Bios the lowest at -35.05%.

Peers: The peers of Remus Pharma are Hester Bios, Themis Medicare, Lincoln Pharma., Wanbury, Kopran, Kilitch Drugs, Bharat Parenter., Shukra Pharma., Fermenta Biotec.<BR><BR>Quality Snapshot: Excellent management risk is observed at Lincoln Pharma. and Kilitch Drugs, while Average management risk is found at Hester Bios, Themis Medicare, Wanbury, Kopran, Bharat Parenter., Shukra Pharma., and Fermenta Biotec. Below Average management risk is noted at Kilitch Drugs. Growth is Excellent at Remus Pharma. and Kilitch Drugs, while Average growth is seen at Wanbury and the rest. Below Average growth is present at Hester Bios, Themis Medicare, Lincoln Pharma., Kopran, Bharat Parenter., and Fermenta Biotec. Capital Structure is Excellent at Lincoln Pharma. and Remus Pharma., Good at Themis Medicare, Kopran, Kilitch Drugs, and Shukra Pharma., while Below Average is noted at Wanbury and Fermenta Biotec, and Average at Bharat Parenter.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Wanbury at 39.83%, while the lowest is Hester Bios at -35.05%. Remus Pharma's 1-year return is -6.72%, which is higher than Hester Bios but lower than Wanbury. Additionally, the six-month return is negative for Hester Bios, Themis Medicare, Lincoln Pharma., Kopran, and Fermenta Biotec.

Who are the top shareholders of the Remus Pharma.?

The top shareholders of Remus Pharma include promoter Shah Arpit Deepakkumar with 17.63%, six foreign institutional investors with a combined 4.77%, and India Emerging Giants Fund Limited as the largest public shareholder at 4.41%. Individual investors own 19.18%, with no pledged promoter holdings or mutual funds involved.

The top shareholders of Remus Pharma include the promoters, who hold the majority of the shares. The promoter with the highest holding is Shah Arpit Deepakkumar, owning 17.63%. Additionally, there are six foreign institutional investors (FIIs) holding a combined 4.77% of the shares. The highest public shareholder is India Emerging Giants Fund Limited, which holds 4.41%. Individual investors collectively own 19.18% of the company. Notably, there are no pledged promoter holdings and no mutual funds currently involved.

How big is Remus Pharma.?

As of 24th July, Remus Pharmaceuticals Ltd has a market capitalization of 1,063.00 Cr, classifying it as a Small Cap company. There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.

As of 24th July, <BR><BR>Market Cap: Remus Pharmaceuticals Ltd has a market capitalization of 1,063.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 86.86 Cr and Total Assets valued at 256.43 Cr.

Is Remus Pharma. overvalued or undervalued?

As of August 28, 2025, Remus Pharma is considered undervalued with an attractive valuation grade, highlighted by a PE ratio of 36.48 and strong financial metrics, despite a year-to-date return of -28.46%.

As of 28 August 2025, Remus Pharma's valuation grade has moved from fair to attractive, indicating a more favorable assessment of its market position. The company is currently considered undervalued, particularly in light of its strong financial metrics. Key ratios include a PE ratio of 36.48, an EV to EBITDA of 22.82, and a PEG ratio of 0.88, which suggests that the stock is trading at a reasonable price relative to its growth potential.<BR><BR>In comparison to its peers, Remus Pharma's valuation stands out, especially against Sun Pharma, which has a PE ratio of 33.18 and is deemed expensive, and Cipla, which is also attractive with a PE of 23.65. Despite recent underperformance, with a year-to-date return of -28.46% compared to the Sensex's 3.62%, the company's strong ROCE of 63.45% and ROE of 33.47% indicate robust operational efficiency and profitability, reinforcing the case for its undervaluation.

How has been the historical performance of Remus Pharma.?

Remus Pharma experienced significant growth from March 2024 to March 2025, with net sales increasing to 620.36 Cr from 212.94 Cr, and profit after tax rising to 38.42 Cr from 24.28 Cr. Key financial metrics, including earnings per share and total assets, also showed substantial improvement.

Answer:<BR>The historical performance of Remus Pharma shows significant growth from the fiscal year ending March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Remus Pharma reported net sales of 620.36 Cr, a substantial increase from 212.94 Cr in March 2024. The total operating income mirrored this growth, reaching 620.36 Cr compared to 212.94 Cr the previous year. Total expenditure also rose to 574.67 Cr from 183.98 Cr, with notable increases in the purchase of finished goods and other expenses. Operating profit (PBDIT) increased to 50.67 Cr from 31.79 Cr, while profit before tax rose to 47.34 Cr from 30.17 Cr. The profit after tax also saw an increase, reaching 38.42 Cr compared to 24.28 Cr in the prior year. The consolidated net profit for March 2025 was 29.07 Cr, up from 20.52 Cr. Earnings per share improved significantly to 24.68 from 17.45, and the book value per share adjusted to 217.2 from 134.09. On the balance sheet, total assets increased to 432.64 Cr from 333.11 Cr, and total liabilities rose to 432.64 Cr from 333.11 Cr. Cash flow from operating activities improved to 6.00 Cr from 1.00 Cr, contributing to a closing cash and cash equivalent of 7.00 Cr, up from 4.00 Cr. Overall, these metrics indicate a strong upward trend in Remus Pharma's financial performance over the year.

Is Remus Pharma. technically bullish or bearish?

As of December 1, 2025, the market trend is mildly bearish, with mixed signals from indicators like the weekly MACD and RSI, while key resistance levels remain unbroken.

As of 1 December 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD indicating a mildly bullish signal, while the moving averages on the daily chart remain bearish. The RSI shows a bullish signal on the monthly timeframe but no signal on the weekly, which adds to the mixed signals. Bollinger Bands and KST both indicate a mildly bearish stance on the weekly, and Dow Theory confirms a mildly bearish trend as well. Overall, the indicators suggest a lack of strong bullish momentum, with the price struggling below key resistance levels.

Why is Remus Pharmaceuticals Ltd falling/rising?

As of 04-Mar, Remus Pharmaceuticals Ltd's stock price is at 596.00, down 1.88%, and has significantly underperformed, with a year-to-date decline of 15.12% and a 37.38% drop over the past year. Despite increased investor participation, the stock continues to trend downward, hitting a new 52-week low and trading below all key moving averages.

As of 04-Mar, Remus Pharmaceuticals Ltd's stock price is falling, currently at 596.00, which reflects a decrease of 11.4 or 1.88%. The stock has underperformed significantly over various time periods, with a year-to-date decline of 15.12% compared to a 6.31% drop in the benchmark Sensex. Over the past year, the stock has plummeted by 37.38%, while the Sensex has gained 10.86%. <BR><BR>Today, the stock hit a new 52-week low of Rs.590, indicating a continued downward trend. Additionally, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, further suggesting a bearish outlook. Although there has been a notable increase in investor participation, with delivery volume rising by 720.75% against the 5-day average, this has not translated into a positive price movement. Overall, these factors contribute to the stock's decline.

Which are the latest news on Remus Pharma.?